Home › Compare › BIIO vs EQR

BIIO vs EQR: Dividend Comparison 2026

BIIO yields 2000000.00% · EQR yields 5.87%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BIIO wins by $4.879226400974806e+39M in total portfolio value
10 years
BIIO
BIIO
● Live price
2000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.879226400974806e+39M
Annual income
$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00
Full BIIO calculator →
EQR
EQR
● Live price
5.87%
Share price
$59.15
Annual div
$3.47
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.8K
Annual income
$5,475.61
Full EQR calculator →

Portfolio growth — BIIO vs EQR

📍 BIIO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBIIOEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BIIO + EQR cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
BIIO pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BIIO
Annual income on $10K today (after 15% tax)
$170,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/yr
EQR
Annual income on $10K today (after 15% tax)
$499.01/yr
After 10yr DRIP, annual income (after tax)
$4,654.27/yr
At 15% tax rate, BIIO beats the other by $4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BIIO + EQR for your $10,000?

BIIO: 50%EQR: 50%
100% EQR50/50100% BIIO
Portfolio after 10yr
$2.439613200487403e+39M
Annual income
$2,439,373,269,665,485,000,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.99%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

BIIO
No analyst data
Altman Z
0.0
Piotroski
2/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+18.9% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BIIO buys
0
EQR buys
0
No recent congressional trades found for BIIO or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBIIOEQR
Forward yield2000000.00% ✓5.87%
Annual dividend / share$2.00$3.47 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8% ✓
Portfolio after 10y$4.879226400974806e+39M$47.8K ✓
Annual income after 10y$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00 ✓$5,475.61
Total dividends collected$4.879195005460081e+39M$23.0K ✓
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: BIIO vs EQR ($10,000, DRIP)

YearBIIO PortfolioBIIO Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$200,010,700$200,000,000.00$11,380$679.82+$200.00M → BIIO
2$3,738,731,768,458$3,738,517,757,009.35$13,014$837.25+$3738731.76M → BIIO
3$65,315,062,866,930,490$65,311,062,423,938,240.00$14,961$1,036.20+$65315062866.92M → BIIO
4$1,066,400,830,062,625,000,000$1,066,330,942,945,357,500,000.00$17,297$1,289.22+$1066400830062625.00M → BIIO
5$16,272,182,796,453,826,000,000,000$16,271,041,747,565,660,000,000,000.00$20,121$1,613.15+$16272182796453826560.00M → BIIO
6$232,054,240,113,661,900,000,000,000,000$232,036,828,878,069,680,000,000,000,000.00$23,561$2,030.84+$2.3205424011366188e+23M → BIIO
7$3,092,799,066,104,688,500,000,000,000,000,000$3,092,550,768,067,767,400,000,000,000,000,000.00$27,783$2,573.54+$3.0927990661046884e+27M → BIIO
8$38,524,105,697,352,694,000,000,000,000,000,000,000$38,520,796,402,351,967,000,000,000,000,000,000,000.00$33,013$3,284.39+$3.8524105697352695e+31M → BIIO
9$448,468,826,014,798,700,000,000,000,000,000,000,000,000$448,427,605,221,702,600,000,000,000,000,000,000,000,000.00$39,547$4,223.51+$4.484688260147987e+35M → BIIO
10$4,879,226,400,974,806,000,000,000,000,000,000,000,000,000,000$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00$47,791$5,475.61+$4.879226400974806e+39M → BIIO

BIIO vs EQR: Complete Analysis 2026

BIIO — Stock

Bionovate Technologies Corp., a medical device company, focuses on developing automated treatment for age spots. It intends to develop automated computerized system that treats age spots anywhere on the body. The company targets to sell its systems to physicians and spas worldwide. The company was formerly known as MJP International Ltd. and changed its name to Bionovate Technologies Corp. in December 2017. Bionovate Technologies Corp. was founded in 2010 and is based in Cham, Switzerland. As of October 7, 2020, Bionovate Technologies Corp. operates as a subsidiary of Human Data AG.

Full BIIO Calculator →

EQR — REIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this BIIO vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BIIO vs SCHDBIIO vs JEPIBIIO vs OBIIO vs KOBIIO vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.